Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Testing effectiveness (Phase 2)Study completedNCT00811135
What this trial is testing

Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 88
Large-scale testing (Phase 3)Ended earlyNCT03199885
What this trial is testing

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaMetastatic HER2-Positive Breast CarcinomaRecurrent Breast Adenocarcinoma+5 more
National Cancer Institute (NCI) 190
Testing effectiveness (Phase 2)Ended earlyNCT00138125
What this trial is testing

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 2
Testing effectiveness (Phase 2)Study completedNCT00915018
What this trial is testing

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 479
Testing effectiveness (Phase 2)Ended earlyNCT01290718
What this trial is testing

Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 4
Large-scale testing (Phase 3)Ended earlyNCT02144012
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 49
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing

The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246
Large-scale testing (Phase 3)Study completedNCT00391092
What this trial is testing

Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 424
Early research (Phase 1)Study completedNCT06570031
What this trial is testing

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer+1 more
Ono Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)UnknownNCT04942899
What this trial is testing

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Who this might be right for
Metastasis Breast
Assiut University 70
Large-scale testing (Phase 3)Active Not RecruitingNCT06760637
What this trial is testing

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Who this might be right for
Breast Cancer
Pfizer 1,035
Large-scale testing (Phase 3)Study completedNCT01572038
What this trial is testing

Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 1,436
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07545044
What this trial is testing

JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc. 60
Not applicableStudy completedNCT01777958
What this trial is testing

HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 135
Large-scale testing (Phase 3)Study completedNCT01120184
What this trial is testing

Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,095
Large-scale testing (Phase 3)Study completedNCT00785291
What this trial is testing

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+6 more
National Cancer Institute (NCI) 799
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Testing effectiveness (Phase 2)Study completedNCT00696072
What this trial is testing

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Who this might be right for
Metastatic Breast Cancer
Bristol-Myers Squibb 120
Testing effectiveness (Phase 2)Study completedNCT01269346
What this trial is testing

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 52
Large-scale testing (Phase 3)Looking for participantsNCT05838066
What this trial is testing

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Who this might be right for
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc. 880
Next Page